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Folate, Vitamin B12, and Homocysteine as 
Risk Factors for Cognitive Decline in the Elderly 
 
 
 
ObjectiveᄏCross-sectional studies have shown that the dysregulation of one-carbon me-
tabolism is associated with cognitive impairment. However, the findings of longitudinal stud-
ies investigating this association have been inconsistent. This study investigated the 
prospective associations between cognitive decline and the levels of folate, vitamin B12 
and homocysteine both at baseline and over course of the study period. 
MethodsᄏA total of 607 (83%) elderly individuals were selected from a group of 732 eld-
erly individuals without dementia at baseline and followed over a 2.4-year study period. The 
Mini-Mental State Examination (MMSE) was administered to the subjects, and the serum 
levels of folate, vitamin B12 and homocysteine were assayed both at baseline and at follow-
up examinations. Covariates included demographic data, disability, depression, alcohol 
consumption, physical activity, vascular risk factors, serum creatinine level, vitamin intake, 
and apolipoprotein E genotype. 
ResultsᄏCognitive decline was associated with decreasing quintiles of folate at baseline, a 
relative decline in folate and an increase in homocysteine across the two examinations after 
adjustment for relevant covariates. 
ConclusionᄏThese results suggest that folate and homocysteine are involved in the etiol-
ogy of cognitive decline in the elderly. 
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Introduction 
 
Folate, vitamin B12, and homocysteine are involved in the one-carbon transfer (me-
thylation) reactions that are necessary for the production of monoamine neurotransmit-
ters, phospholipids, and nucleotides. Homocysteine may also have a direct neurotoxic
effect. Therefore, hyperhomocysteinemia and deficiencies in folate and vitamin B12 may
contribute to the pathogenesis of cognitive impairment. Several cross-sectional studies 
have found significant associations between the adverse profiles of these factors and
cognitive impairment.
1-5 However, the direction of cause and effect in these associations 
cannot be ascertained from these findings because changes in appetite and diet asso-
ciated with cognitive impairment may result in nutritional deficiencies. The results from
prospective studies have been controversial: some studies found significant associations 
between these factors and cognitive decline,
6 while others did not.
7 There has been little 
research into the changes in the factors associated with cognitive decline. 
In a previous community study, we found that cognitive impairment was significantly 
associated with lower folate and higher homocysteine levels, but not with the levels of
vitamin B12.
8 We subsequently followed the study cohort over a 2-year period and 
investigated the associations between cognitive decline and the levels of folate, vitamin 
B12 and homocysteine at baseline and throughout the follow-up period.    
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 Methods 
 
A community based prospective survey was carried 
out in Gwangju, South Korea between 2001 and 2003 in 
collaboration with the 10/66 Dementia in Developing 
Countries Research Program.
9 All participants gave writ-
ten formal informed consent at each examination. This 
study was approved by the Chonnam National Univer-
sity Hospital Institutional Review Board. 
 
Baseline evaluation 
The sampling procedure and measurements of the ba-
seline cross-sectional survey have been described previ-
ously.
10,11 In brief, 732 community residents aged 65 or 
over within two geographic catchment areas (one urban, 
one rural) of Gwangju, South Korea were identified from 
national resident registration lists. The examinations in-
cluded cognitive function assessments; blood samples 
for analyses of folate, vitamin B12, and homocysteine; and 
a formal assessment of potential confounding factors. 
Cognitive functioning was assessed using the Korean 
version of the Mini-Mental State Examination (MMSE-
K).
12 The MMSE-K has been specifically developed and 
evaluated for the assessment of cognitive functioning in 
older Korean populations, with revised items taking low 
education levels and high rates of illiteracy into account. 
Blood samples were collected in a fasting state and 
were obtained in the morning when possible. The blood 
samples were drawn into ethylenediaminetetra acetic acid 
(EDTA) tubes, centrifuged, separated into plasma aliquots, 
and stored at -70℃ within 2 hours of collection. Bio-
chemical assays were carried out after three years. The 
levels of serum folate and vitamin B12 were determined 
using an immunoassay, and highperformance liquid chro-
matography was used to measure total plasma homocys-
teine levels. Apolipoprotein E (APOE) genotyping was 
carried out, and the samples were classified according to 
the presence or absence of the APOE e4 allele. 
Demographic data on age, gender, and education level 
were recorded. Disability was assessed by the Korean 
version of the World Health Organization Disability As-
sessment Schedule II (WHODAS II).
13 Depression was 
assessed using the community version of the Geriatric 
Mental State schedule (GMS).
14,15 As in other studies, a 
‘stage one’ (non-hierarchical) confidence level of 3 or 
above from the Automated Geriatric Examination for 
Computer Assisted Taxonomy (AGECAT) algorithm was 
used to define depression. Information on the subjects’ 
smoking history and current smoking status was obtain-
ed. A lifetime history of alcohol consumption was ob-
tained from the participants, and the information provid-
ed was confirmed by their family members if possible. 
A high intake of alcohol was defined on the basis of 
consumption over the previous three months of greater 
than 14 drinks per week for men or greater than 7 drinks 
per week for women. Information on daily physical activ-
ity, including both work and leisure activities, was ob-
tained, and the subjects were classified as having a low 
level of physical activity on the basis of a predominant-
ly sedentary lifestyle. For the assessment of vascular risk 
factors and disorders, a summary vascular risk score was 
calculated by summing self-reported disorders (stroke, 
heart disease, hypertension, diabetes), measured obesity 
(body mass index > 25 kg/m
2) and hypercholesterolemia 
(fasting cholesterol > 200 mg/dl). Serum creatinine levels 
were also evaluated because impaired renal function may 
elevate serum metabolite levels independent of vitamin 
intake. 
 
Follow-up evaluation 
The follow-up evaluation was carried out in 2003.
16 
The mean (SD) follow-up period was 2.4 (0.3) years. At-
tempts were made to follow-up all previous participants. 
The procedures used in the follow-up evaluation were 
identical to those used in the baseline assessment. The 
MMSE-K scores were reassessed, and changes in the 
MMSE-K scores (score in 2003 minus that in 2001) were 
calculated. Further blood samples for folate, vitamin B12 
and homocysteine were collected, centrifuged within 
one hour and stored at -70℃. Assays were carried out 
after one year. Data on the use of vitamin supplements 
was obtained by taking an inventory of all prescription 
and nonprescription medications taken within the past 
one month. 
 
Statistical analysis 
Associations between cognitive decline and baseline 
characteristics were investigated using t-, Pearson’s cor-
relation, or Spearman’s correlation tests as appropriate. 
Univariate associations between changes in the MMSE 
score (as a continuous dependent variable) and baseline 
quintiles of folate, vitamin B12 and homocysteine were 
estimated by analysis of variance (ANOVA). To inves-
tigate the associations between changes in the levels of 
folate, vitamin B12 and homocysteine, the changes in 
these three values (value in 2003 minus that in 2001) were 
also recategorized by quintiles. Univariate associations 
between changes in the MMSE score and changes in the 
quintiles of folate, vitamin B12 and homocysteine were 
also estimated by ANOVA. For the multivariate analysis, 
B coefficients (with 95% CI) were calculated for the 
associations between changes in the MMSE score from 
baseline and changes in the quintiles of folate, vitamin 
B12 and homocysteine in linear regression models after  
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adjustment for relevant independent variables. Statisti-
cal analyses were carried out using SPSS 12.0 software. 
 
Results 
 
A total of 607 (83%) of the 732 participants recruited 
at baseline completed all follow-up evaluations and com-
prised the study sample. Of the remaining 125 partici-
pants who were lost during the follow-up, contact could 
not be established with 45 (36%), 25 (20%) had died, 
25 (20%) refused to participate, 21 (17%) changed their 
address, and 9 (7%) were not well enough to participate. 
The baseline characteristics of the followed-up sample 
are shown in the first column of Table 1. There were no 
significant differences in baseline characteristics between 
the participants and non-participants at follow-up, includ-
ing the baseline blood assays of interest (data not sho-
wn, all p>0.05). 
The mean (SD) change in MMSE-K score among the 
607 participants over the 2.4-year follow-up was -1.3 
(3.9) points. Associations between baseline characteristics 
and cognitive decline are displayed in the second th-
rough third columns of Table 1. Cognitive decline was 
significantly associated with more severe disability, higher 
vascular risk scores and the presence of the APOE e4 
allele. There was no association between cognitive de-
cline and vitamin intake at the final follow-up (p= 
0.456). 
The two graphs in Figure 1 plot the mean change in 
MMSE-K score according to the baseline quintiles of 
folate, vitamin B12 and homocysteine, and the changes 
in the quintiles in these levels over the follow-up period. 
The mean changes in the MMSE-K scores across ascend-
ing quintiles of baseline folate levels were -2.4, -1.5, 
-1.1, -0.8 and -0.7 (F=2.728; p=0.029). The mean 
changes in the MMSE-K scores across ascending quin-
TABLE 1. Baseline characteristics and associations with cognitive decline
Source Data  (N=607) Statistical  coefficient  p* 
Demographic characteristics       
Age, mean (SD) years  71.9 (5.1) r =-0.015 0.730 
Female sex, N (%) 348  (57.3) t =-1.437 0.115 
Education, median (IQR) years  2 (0-6) rho=-0.043 0.324 
Assessment scales       
WHODAS II, median (IQR) scores  2.1 (0-7) rho=0.127 0.004 
GMS depression, N (%) 73  (12.0) t =0.442 0.659 
Lifestyle characteristics       
Current smoker, N (%) 252  (41.5) t =1.101 0.271 
High alcohol intake, N (%) 181  (29.8) T =1.795 0.073 
Low physical activity, N (%) 166  (27.3) T =0.164 0.869 
Vascular risk score, median (IQR) 1  (0-2) rho=-0.086 0.049 
Serum creatinine, mean (SD) mg/dL  0.8 (0.3) r =-0.062 0.159 
APOE e4 allele, N (%) 88  (17.0) t =2.174 0.030 
*By t-, Pearson’s correlation, or Spearman’s correlation tests as appropriate. IQR: interquartile range, WHODAS II: World Health Organi-
zation Disability Assessment Schedule, GMS: Geriatric Mental State schedule, APOE: apolipoprotein E 
 
FIGURE 1. Mean changes in Korean version of Mini-Mental State Examination (MMSE-K) scores according to baseline levels of folate, 
vitamin B12 and homocysteine and changes in these levels over a 2-year follow-up period. 
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tiles of baseline vitamin B12 levels were -2.2, -1.3,  
-1.1, -1.1 and -0.9 (F=1.584; p=0.177). The mean 
changes in the MMSE-K scores across ascending quin-
tiles of baseline homocysteine levels were -0.8, -0.9, 
-1.4, -1.6 and -1.7 (F=1.113; p=0.350). The mean 
changes in the MMSE-K scores across ascending quin-
tiles of change in folate levels (decrease to increase) 
over the follow-up period were -2.2, -1.7, -1.0, -0.9 
and -0.7 (F=2.571; p=0.037). The mean changes in the 
MMSE-K scores across ascending quintiles of change in 
vitamin B12 levels were -1.5, -1.4, -1.4, -1.3 and -0.8 
(F=0.532; p=0.712). The mean changes in the MMSE-
K scores across ascending quintiles of change in homo-
cysteine levels were -0.5, -0.9, -1.0, -2.0 and -2.1 (F= 
3.159; p=0.014). 
The adjusted associations between these factors are 
displayed in Table 2. In summary, cognitive decline was 
associated with decreasing quintiles of folate at baseline, 
a relative decline in folate and an increase in homocys-
teine levels across the two examinations. These associa-
tions did not change after adjustment for disability, vas-
cular risk scores, and APOE genotype. 
 
Discussion 
 
In this prospective study of a community population, 
lower folate levels predicted cognitive decline over a 
2.4-year follow-up period, but no associations were 
found between baseline cognitive decline and the levels 
of vitamin B12 or homocysteine. Over the follow-up pe-
riod, cognitive decline occurred more frequently in sub-
jects showing a relative decline in folate or a relative 
increase in homocysteine levels. 
A particular strength of this study was that prospec-
tive data were obtained not only for cognitive status, but 
also for the exposures of interest. Furthermore, a large 
number of potential confounding factors were considered 
in the analyses. The follow-up rate was reasonable and 
did not differ with respect to the risk factors of interest. 
The principal limitations of the study were that cogni-
tive function was assessed by the MMSE-K alone and 
detailed constituents of vitamin preparations were not 
collected. In addition, micronutrient values were only 
measured at two time points, which might have caused 
measurement errors or may not reflect dynamic changes 
from baseline to follow-up. 
A common finding of previous cross-sectional clinical 
and community studies has been that lower levels of 
folate, and/or vitamin B12, and/or higher levels of homo-
cysteine are associated with cognitive impairment.
1-5 Cro-
ss-sectional analyses of the same participants from the 
previous study showed similar results.
8 However, cross-
sectional studies are limited in the extent to which ca-
usal relationships can be inferred since impaired cog-
nitive states may lead to dietary changes that can influ-
ence the observed blood levels. The findings from more 
recent prospective studies have been inconsistent. 
Folate is important in one-carbon metabolism, and 
methylation reactions involving folate may be important 
in the formation and maintenance of neuronal and glial 
membrane reactions.
17 Most longitudinal studies have fo-
und associations between folate and cognitive decline,
18-20 
but one study did not.
7 In our study, this association was 
not explained by other potential confounding factors, 
such as disability, vascular risk factors, and APOE geno-
type. The previous studies were primarily focused on 
homocysteine levels. Homocysteine is not only a marker 
of dysfunction in one-carbon metabolism but may also 
exert direct neurotoxic effects. The results of longitudi-
nal studies have been inconsistent, with some finding 
significant associations,
6,18,20,21 but others finding no as-
sociation.
7,22 Baseline homocysteine levels did not pre-
dict cognitive decline in the present study. Vitamin B12 
is required for the synthesis of S-adenosylmethionine, 
which is the major methyl donor in many important me-
thylation reactions in the central nervous system. How-
ever, cross-sectional associations with cognitive impairment 
have not been replicated in most longitudinal studies,
7,19 
including ours. An important limitation of most research 
is that circulating B12 is only a proxy marker of cobal-
amin deficiency at the cellular level. It has been sug-
gested that holotranscobalamin may be a more accurate 
marker of risk.
23 We did not have data on this factor, and 
therefore, negative findings with respect to B12 should 
TABLE 2. Linear regression models for the associations between cognitive decline and baseline folate levels and changes in folate/ 
homocysteine quintiles over the 2.4-year follow-up period (N=607) 
B (95% CI) for cognitive decline per quintile difference 
 
Baseline folate (lower)  Changed folate (lower) Changed  homocysteine  (higher) 
Unadjusted  -0.38 (-0.63, -0.14)  -0.38 (-0.63, -0.14)  -0.42 (-0.66, -0.17) 
Model 1: adjusted for WHODAS II  -0.36 (-0.61, -0.12)  -0.37 (-0.61, -0.13)  -0.43 (-0.67, -0.18) 
Model 2: Model 1 plus vascular risk score  -0.37 (-0.61, -0.13)  -0.36 (-0.60, -0.12)  -0.42 (-0.66, -0.18) 
Model 3: Model 2 plus APOE e4  -0.36 (-0.61, -0.12)  -0.37 (-0.61, -0.12)  -0.41 (-0.65, -0.17) 
WHODAS II: World Health Organization Disability Assessment Schedule, APOE: apolipoprotein E 
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be treated with caution. 
Very few studies have examined the changes in the 
levels of these factors. In a recent longitudinal study, 
assays were carried out six years apart, and a decrease 
in folate and an increase in homocysteine were found to 
be associated with cognitive decline over the same peri-
od.
19 In our study, cognitive decline was associated with 
unfavorable changes in these factors. These changes were 
stronger correlates than baseline levels. Although our 
findings may be explained by the effects of such changes 
on neurodegenerative processes, they more strongly 
suggest an effect of degenerative processes on the levels 
of these factors. However, it is possible that both pro-
cesses occur because the effects of neurodegenerative 
processes (for example on dietary intake) may give rise 
to an adverse biochemical environment, which, in turn, 
induces further neurodegeneration or exacerbates its ef-
fects on cognitive function. Further research is required in 
order to clarify these longitudinal interrelationships. In 
the meantime, attention needs to be paid to the nutrition-
al status of people with cognitive decline from the time 
of detection, regardless of whether this is a cause or ef-
fect of their condition. 
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